Last checked at 29 Apr 2021 07:00
ReNeuron Group plc
("ReNeuron" or the "Company")
Initiation of research by Allenby Capital
ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, announces the initiation of research by Allenby Capital Limited, the Company's joint broker.
The research is available to view on the ReNeuron website here: http://www.reneuron.com/investors/analyst-research-and-presentations/
Contacts:
ReNeuron | www.reneuron.com/investors |
Olav Hellebø, Chief Executive Officer | Via Walbrook PR |
Michael Hunt, Chief Financial Officer |
|
|
|
Stifel Nicolaus Europe Limited (NOMAD and Joint Broker) Ben Maddison, Stewart Wallace | +44 (0)20 7710 7600
|
|
|
Allenby Capital Limited (Joint Broker) James Reeve/George Payne (Corporate Finance) Tim Sohal (Sales & Corporate Broking) | +44 (0)20 3328 5656 |
Walbrook PR (Media & Investor Relations) | +44 (0)20 7933 8780 or reneuron@walbrookpr.com |
Paul McManus, Alice Woodings | +44 (0)7980 541 893 / +44 (0)7407 804 654 |
About ReNeuron
ReNeuron is a global leader in cell-based therapeutics, harnessing its unique stem cell technologies to develop 'off the shelf' stem cell treatments, without the need for immunosuppressive drugs. The Company's lead cell therapy candidate is in clinical development for the blindness-causing disease, retinitis pigmentosa.
ReNeuron is also advancing its proprietary exosome technology platform as a potential delivery system for drugs that treat diseases of the brain. he Company also has the ability through its conditionally immortalised induced pluripotent stem cell (iPSC) platform to make any tissue cells of choice; in-house programmes are focused on treatments for blood cancers and diabetes.
ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. For further information visit www.reneuron.com